Altasciences and ITR Laboratories have entered a strategic alliance to provide clients with an integrated service offering for drug development programs from lead candidate selection through to early stage clinical trials. A single, coordinated team will work with clients throughout the drug development process in an effort to minimize delays during the transition from nonclinical to clinical development.

“Few organizations can offer an integrated early development solution which includes expertise in both nonclinical and clinical testing, along with personalized service. ITR and Altasciences are customer-centric full-service companies that provide the necessary focused expertise from nonclinical studies to first-in-human and proof-of-concept clinical programs, which we believe will benefit our Sponsors with customized turn-key solutions,” said Chris Perkin, chief executive officer at Altasciences.

“Both organizations have collaborated extensively over the past 25 years and share the same approach to customer service and flexibility – our company structure allows for quick responses and accommodates last-minute changes easily. ITR and Altasciences have already worked together to provide Bioanalytical services for complex analysis on preclinical studies that will then extend to the clinical programs, this alliance was a natural extension from which many of our clients have already benefitted,” said Ginette Bain, senior vice president at ITR Laboratories Canada.